2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations

키워드

참고문헌 (190)

1. "Hypertension (CG127):clinical management of primary hypertension in adults"[URL]
2. Clement DL, "Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension", N Engl J Med, 348, pp.2407~2415 (2003)
3. Wang YC, "Prevalence of masked hypertension among US adults with nonelevated clinic blood pressure", Am J Epidemiol, 185, pp.194~202 (2017)
4. Banegas JR, "Relationship between clinic and ambulatory blood-pressure measurements and mortality", N Engl J Med, 378, pp.1509~1520 (2018)
5. Verdecchia P, "The natural history of white-coat hypertension in the long term", Blood Press Monit, 10, pp.65~66 (2005)
6. Ohkubo T, "Prognosis of"masked"hypertension and"white-coat"hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study", J Am Coll Cardiol, 46, pp.508~515 (2005)
7. Mancia G, "2013ESH", ESC guidelines for the management of arterial hypertension : the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC), 2013, pp.31, 1281~1357
8. Asayama K, "Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population", Hypertension, 64, pp.935~942 (2014)
9. Viera AJ, "Reproducibility of masked hypertension among adults 30 years or older", Blood Press Monit, 19, pp.208~215 (2014)
10. Tuomilehto J, "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance", N Engl J Med, 344, pp.1343~1350 (2001)
11. Knowler WC, "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", N Engl J Med, 346, pp.393~403 (2002)
12. Dagenais GR, "Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose : results of the diabetes REduction assessment with ramipril and rosiglitazone medication(DREAM)trial", Diabetes Care, 31, pp.1007~1014 (2008)
13. McMurray JJ, "Effect of valsartan on the incidence of diabetes and cardiovascular events", N Engl J Med, 362, pp.1477~1490 (2010)
14. Lonn EM, "Bloodpressure lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2009~2020 (2016)
15. Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity", Circulation, 120, pp.1640~1645 (2009)
16. Lee SY, "Appropriate waist circumference cutoff points for central obesity in Korean adults", Diabetes Res Clin Pract, 75, pp.72~80 (2007)
17. Lee SE, "Trends in the prevalence of metabolic syndrome and its components in South Korea : findings from the Korean National Health Insurance Service database(2009-2013)", PLoS One, 13, pp.e0194490~ (2018)
18. Cha MJ, "Prevalence and clinical characteristics of metabolic syndrome in Korean hypertensive patients", J Korean Soc Hypertens, 15, pp.8~ (2009)
19. Gami AS, "Metabolic syndrome and risk of incident cardiovascular events and death : a systematic review and meta-analysis of longitudinal studies", J Am Coll Cardiol, 49, pp.403~414 (2007)
20. Ford ES, "Metabolic syndrome and incident diabetes : current state of the evidence", Diabetes Care, 31, pp.1898~1904 (2008)
21. Cheung BM, "Development of diabetes in Chinese with the metabolic syndrome : a 6-year prospective study", Diabetes Care, 30, pp.1430~1436 (2007)
22. Mukai N, "Impact of metabolic syndrome compared with impaired fasting glucose on the development of type 2 diabetes in a general Japanese population : the Hisayama study", Diabetes Care, 32, pp.2288~2293 (2009)
23. Gress TW, "Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study", N Engl J Med, 342, pp.905~912 (2000)
24. Weycker D, "Excess risk of diabetes in persons with hypertension", J Diabetes Complicat, 23, pp.330~336 (2009)
25. Emdin CA, "Blood pressure lowering in type 2 diabetes : a systematic review and meta-analysis", JAMA, 313, pp.603~615 (2015)
26. Turner R, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38", BMJ, 317, pp.703~713 (1998)
27. Brunstrom M, "Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus : systematic review and meta-analyses", BMJ, 352, pp.i717~ (2016)
28. Cushman WC, "Effects of intensive blood-pressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
29. Patel A, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus(the ADVANCE trial) : a randomised controlled trial", Lancet, 370, pp.829~840 (2007)
30. Group TG., "Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy", Lancet, 349, pp.1857~1863 (1997)
31. Turnbull F, "Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus : results of prospectively designed overviews of randomized trials", Arch Intern Med, 165, pp.1410~1419 (2005)
32. Turnbull F., "Blood pressure lowering treatment Trialists C. effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials", Lancet, 362, pp.1527~1535 (2003)
33. Buckley LF, "Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP", Diabetes Care, 40, pp.1733~1738 (2017)
34. Lindholm LH, "Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study(LIFE) : a randomised trial against atenolol", Lancet, 359, pp.1004~1010 (2002)
35. Berl T, "Cardiovascular outcomes in the Irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy", Ann Intern Med, 138, pp.542~549 (2003)
36. Palmer SC, "Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease : a network meta-analysis", Lancet, 385, pp.2047~2056 (2015)
37. Grundy SM, "Diabetes and cardiovascular disease : a statement for healthcare professionals from the American Heart Association", Circulation, 100, pp.1134~1146 (1999)
38. Sowers JR, "Treatment of cardiovascular and renal risk factors in the diabetic hypertensive", Hypertension, 40, pp.781~788 (2002)
39. Adler AI, "Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes(UKPDS 36) : prospective observational study", BMJ, 321, pp.412~419 (2000)
40. Hansson L, "Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial", Lancet, 351, pp.1755~1762 (1998)
41. Yusuf S, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", N Engl J Med, 342, pp.145~153 (2000)
42. ALLHAT Officers, "Coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)", JAMA, 288, pp.2981~2997 (2002)
43. Beulens JW, "Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus : a randomised controlled trial", Diabetologia, 52, pp.2027~2036 (2009)
44. Pepine CJ, "A calcium channel blocker vs a non-calcium channel blocker hypertension treatment strategy for patients with coronary artery disease. The international verapamil-Trandolapril study (INVEST): a randomized controlled trial", JAMA, 290, pp.2805~2816 (2003)
45. Weber MA, "Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on reninangiotensin system blockade", Blood Press, 25, pp.93~103 (2016)
46. Weber MA, "Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy : a randomised, double-blind, placebo-controlled, phase 3 study", Lancet Diabetes Endocrinol, 4, pp.211~220 (2016)
47. Scheen AJ, "Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes : focus on SGLT2 inhibitors and EMPA-REG OUTCOME", Diabetes Res Clin Pract, 121, pp.204~214 (2016)
48. Williamson JD, "Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >", =75 years : a randomized clinical trial, 2016, pp.315, 2673~2682
49. Weiss J, "Benefits and harms of intensive blood pressure treatment in adults aged 60years or older : a systematic review and meta-analysis", Ann Intern Med, 166, pp.419~429 (2017)
50. Whelton PK, "Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)", JAMA, 279, pp.839~846 (1998)
51. Rakugi H, "Comparison of strict-and mild-blood pressure control in elderly hypertensive patients : a per-protocol analysis of JATOS", Hypertens Res, 33, pp.1124~1128 (2010)
52. SHEP Cooperative Research Group, "Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)", Jama, 265, pp.3255~3264 (1991)
53. Staessen JA, "Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension", Lancet, 350, pp.757~764 (1997)
54. Wing LM, "A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly", N Engl J Med, 348, pp.583~592 (2003)
55. Lithell H, "The study on cognition and prognosis in the elderly(SCOPE) : principal results of a randomized double-blind intervention trial", J Hypertens, 21, pp.875~886 (2003)
56. Saiz LC, "Blood pressure targets for the treatment of people with hypertension and cardiovascular disease", Cochrane Database Syst Rev, 10, pp.CD010315~ (2017)
57. Mancia G, "Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial", Eur Heart J, 37, pp.955~964 (2016)
58. Bangalore S, "Blood pressure targets in patients with coronary artery disease : observations from traditional and Bayesian random effects meta-analysis of randomised trials", Heart, 99, pp.601~613 (2013)
59. Cooper-DeHoff RM, "Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease", JAMA, 304, pp.61~68 (2010)
60. Group SR, "a randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
61. Lewington S, "Agespecific relevance of usual blood pressure to vascular mortality : a metaanalysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)
62. Mancia G, "Blood pressure control and improved cardiovascular outcomes in the international verapamil SR-Trandolapril study", Hypertension, 50, pp.299~305 (2007)
63. Law MR, "Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", BMJ, 338, pp.b1665~ (2009)
64. Borghi C, "Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension", Am J Hypertens, 12, pp.665~672 (1999)
65. Yancy CW, "2017ACC", AHA, AHA guideline for the Management of Heart Failure : a report of the American College of Cardiology, pp.American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America, Circulation[DOI]
66. Lee SE, "Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure", JACC Heart Fail, 5, pp.810~819 (2017)
67. Tocci G, "Development of heart failure in recent hypertension trials", J Hypertens, 26, pp.1477~1486 (2008)
68. Gottdiener JS, "Predictors of congestive heart failure in the elderly : the cardiovascular health study", J Am Coll Cardiol, 35, pp.1628~1637 (2000)
69. Levy D, "The progression from hypertension to congestive heart failure", JAMA, 275, pp.1557~1562 (1996)
70. Writing Committee M, "2016 ACC", AHA, AHA guideline for the Management of Heart Failure : a report of the American College of Cardiology, pp.American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America, Circulation[DOI]
71. Goldstein RE, "Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction", Circulation, 83, pp.52~60 (1991)
72. Camm AJ, "European heart rhythm, association. European Association for Cardio-Thoracic, surgery. Guidelines for the management of atrial fibrillation: the task force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)", Eur Heart J, 31, pp.2369~2429 (2010)
73. Kirchhof P, "Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET", EHRA consensus conference, 2011, pp.106, 1012~1019
74. Camm AJ, "2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation", Eur Heart J, 33, pp.2719~2747 (2012)
75. Manolis AJ, "Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the working group ‘Hypertension arrhythmias and Thrombosis’ of the European Society of Hypertension", J Hypertens, 30, pp.239~252 (2012)
76. Arima H, "Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy : the PROGRESS trial", Stroke, 43, pp.1675~1677 (2012)
77. Vidal-Petiot E, "Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease : an international cohort study", Lancet, 388, pp.2142~2152 (2016)
78. Vemulapalli S, "Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation : results from the ROCKET AF trial", Am Heart J, 178, pp.74~84 (2016)
79. Zanchetti A, "Calcium channel blocker lacidipine slows down progression of asymptomatic carotid atherosclerosis : principal results of the European Lacidipine study on atherosclerosis(ELSA), a randomized, double-blind, long-term trial", Circulation, 106, pp.2422~2427 (2002)
80. Zanchetti A, "Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis : principal results of PHYLLIS--a randomized double-blind trial", Stroke, 35, pp.2807~2812 (2004)
81. Yen CH, "Angiotensin receptor blockades effect on peripheral muscular and central aortic arterial stiffness : a meta-analysis of randomized controlled trials and systematic review", Acta Cardiol Sin, 30, pp.98~107 (2014)
82. Chen X, "Effects of different types of antihypertensive agents on arterial stiffness : a systematic review and meta-analysis of randomized controlled trials", J Thorac Dis, 7, pp.2339~2347 (2015)
83. Boutouyrie P, "Amlodipinevalsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination : the EXPLOR study", Hypertension, 55, pp.1314~1322 (2010)
84. Ong KT, "Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment : a meta-analysis of individual data in 294 patients", J Hypertens, 29, pp.1034~1042 (2011)
85. Shahin Y, "Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections : a meta-analysis and metaregression of randomised controlled trials", Atherosclerosis, 221, pp.18~33 (2012)
86. Karalliedde J, "Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering", Hypertension, 51, pp.1617~1623 (2008)
87. Guerin AP, "Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure", Circulation, 103, pp.987~992 (2001)
88. Murabito JM, "Temporal trends in the incidence of intermittent claudication from 1950 to 1999", Am J Epidemiol, 162, pp.430~437 (2005)
89. Aboyans V, "2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery(ESVS) : document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by : the European stroke organization(ESO)the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology(ESC)and of the European Society for Vascular Surgery(ESVS)", Eur Heart J, 39, pp.763~816 (2018)
90. Bavry AA, "Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease : findings from the INternational VErapamil-SR", Trandolapril STudy, 2010, pp.55, 48~53
91. Thomopoulos C, "Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels -updated overview and meta-analyses of randomized trials", J Hypertens, 34, pp.613~622 (2016)
92. Yusuf S, "Telmisartan, ramipril, or both in patients at high risk for vascular events", N Engl J Med, 358, pp.1547~1559 (2008)
93. Ostergren J, "Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease", Eur Heart J, 25, pp.17~24 (2004)
94. De Buyzere ML, "Management of hypertension in peripheral arterial disease", Prog Cardiovasc Dis, 50, pp.238~263 (2008)
95. Zanchetti A, "Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine : an analysis of findings from the VALUE trial", J Hypertens, 24, pp.2163~2168 (2006)
96. Piller LB, "Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT", J Gen Intern Med, 29, pp.1475~1483 (2014)
97. Thompson AM, "Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension : a meta-analysis", JAMA, 305, pp.913~922 (2011)
98. Paravastu SC, "Beta blockers for peripheral arterial disease", Eur J Vasc Endovasc Surg, 38, pp.66~70 (2009)
99. Radack K, "Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A metaanalysis of randomized controlled trials", Arch Intern Med, 151, pp.1769~1776 (1991)
100. 100, "Management of hypertension in peripheral arterial disease:does the choice of drugs matter?", Eur J Vasc Endovasc Surg, 35, pp.701~708 (2008)
101. Shores J, "Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome", N Engl J Med, 330, pp.1335~1341 (1994)
102. Lewis EJ, "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", N Engl J Med, 345, pp.851~860 (2001)
103. Jafar TH, "Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data", Ann Intern Med, 135, pp.73~87 (2001)
104. Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
105. 김세중, "고혈압 환자에서 만성 신질환의 유병율과신기능 감소의 예측인자", Kidney Research and Clinical Practice, 27(1), pp.20~27 (2008), 대한신장학회
106. 김영주, "한국인 심혈관질환의 유병률과 관련 위험인자: 2005년, 2007년 국민건강영양 조사를 바탕으로", Korean Journal of Health Promotion, 11(3), pp.169~176 (2011), 대한임상건강증진학회
107. Wheeler DC, "Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?", Kidney Int, 83, pp.377~383 (2013)
108. Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
109. Peterson JC, "Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study", Ann Intern Med, 123, pp.754~762 (1995)
110. Wright JT Jr, "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial", JAMA, 288, pp.2421~2431 (2002)
111. Ruggenenti P, "Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease(REIN-2) : multicentre, randomised controlled trial", Lancet, 365, pp.939~946 (2005)
112. Jafar TH, "Progression of chronic kidney disease : the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition : a patient-level meta-analysis", Ann Intern Med, 139, pp.244~252 (2003)
113. Maschio G, "Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency", N Engl J Med, 334, pp.939~945 (1996)
114. Ruggenenti P, "In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR", J Am Soc Nephrol, 10, pp.997~1006 (1999)
115. Krikken JA, "Benefits of dietary sodium restriction in the management of chronic kidney disease", Curr Opin Nephrol Hypertens, 18, pp.531~538 (2009)
116. Boudville N, "Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease", Am J Hypertens, 18, pp.1300~1305 (2005)
117. Gelber RP, "Association between body mass index and CKD in apparently healthy men", Am J Kidney Dis, 46, pp.871~880 (2005)
118. Jones DW, "Body mass index and blood pressure in Korean men and women : the Korean National Blood Pressure Survey", J Hypertens, 12, pp.1433~1437 (1994)
119. Whelton SP, "Effect of aerobic exercise on blood pressure : a meta-analysis of randomized, controlled trials", Ann Intern Med, 136, pp.493~503 (2002)
120. Kosmadakis GC, "Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease", Nephrol Dial Transplant, 27, pp.997~1004 (2012)
121. Chen L, "Alcohol intake and blood pressure : a systematic review implementing a Mendelian randomization approach", PLoS Med, 5, pp.e52~ (2008)
122. Kim YJ, "Association between obesity and chronic kidney disease, defined by both glomerular filtration rate and albuminuria, in Korean adults", Metab Syndr Relat Disord, 15, pp.416~422 (2017)
123. Acelajado MC, "Hypertension in the elderly", Clin Geriatr Med, 25, pp.391~412 (2009)
124. Benvenuto LJ, "Morbidity and mortality of orthostatic hypotension : implications for management of cardiovascular disease", Am J Hypertens, 24, pp.135~144 (2011)
125. Wu JS, "Population-based study on the prevalence and correlates of orthostatic hypotension", hypertension and orthostatic dizziness, 2008, pp.31, 897~904
126. Lawes CM, "Blood pressure and stroke : an overview of published reviews", Stroke, 35, pp.776~785 (2004)
127. Psaty BM, "Health outcomes associated with various antihypertensive therapies used as first-line agents : a network meta-analysis", JAMA, 289, pp.2534~2544 (2003)
128. Wiysonge CSBH, "Beta-blockers for hypertension" (2007)
129. Aronow WS, "Treatment of hypertension and prevention of ischemic stroke", Curr Cardiol Rep, 6, pp.124~129 (2004)
130. National Institute of Neurological D, "Tissue plasminogen activator for acute ischemic stroke", N Engl J Med, 333, pp.1581~1587 (1995)
131. Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
132. Ahmed N, "Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis : retrospective analysis from safe implementation of thrombolysis in stroke-international stroke thrombolysis register(SITS-ISTR)", Stroke, 40, pp.2442~2449 (2009)
133. Robinson TG, "Effects of antihypertensive treatment after acute stroke in the continue or stop poststroke Antihypertensives collaborative study(COSSACS) : a prospective, randomised, open, blinded-endpoint trial", Lancet Neurol, 9, pp.767~775 (2010)
134. He J, "Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke : the CATIS randomized clinical trial", JAMA, 311, pp.479~489 (2014)
135. Chobanian AV, "Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure", Hypertension, 42, pp.1206~1252 (2003)
136. Sandset EC, "The angiotensin-receptor blocker candesartan for treatment of acute stroke(SCAST) : a randomised, placebo-controlled, double-blind trial", Lancet, 377, pp.741~750 (2011)
137. Qureshi AI, "Prevalence of elevated blood pressure in 563, 704 adult patients with stroke presenting to the ED in the United States", Am J Emerg Med, 25, pp.32~38 (2007)
138. Schrader J, "The ACCESS study : evaluation of acute candesartan Cilexetil therapy in stroke survivors", Stroke, 34, pp.1699~1703 (2003)
139. Hankey GJ, "Lowering blood pressure in acute stroke : the SCAST trial", Lancet, 377, pp.696~698 (2011)
140. Jauch EC, "Guidelines for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 870~947
141. "Clinical Practice Guidelines for Stroke"[URL]
142. Larrue V, "Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European cooperative acute stroke study", Stroke, 28, pp.957~960 (1997)
143. The NINDS t-PA Stroke Study Group, "Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke", Stroke, 28, pp.2109~2118 (1997)
144. Adams HP Jr, "Guidelines for the early management of adults with ischemic stroke : a guideline from the American Heart Association", American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups : the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists, 2007, pp.38, 1655~1711
145. Anderson CS, "Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage", N Engl J Med, 368, pp.2355~2365 (2013)
146. Qureshi AI, "Intensive blood-pressure lowering in patients with acute cerebral hemorrhage", N Engl J Med, 375, pp.1033~1043 (2016)
147. Rodriguez-Luna D, "Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage", Eur J Neurol, 20, pp.1277~1283 (2013)
148. Sakamoto Y, "Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage : the stroke acute management with urgent risk-factor assessment and improvementintracerebral hemorrhage study", Stroke, 44, pp.1846~1851 (2013)
149. Tsivgoulis G, "Intensive blood pressure reduction in acute intracerebral hemorrhage : a meta-analysis", Neurology, 83, pp.1523~1529 (2014)
150. Ohwaki K, "Blood pressure management in acute intracerebral hemorrhage : relationship between elevated blood pressure and hematoma enlargement", Stroke, 35, pp.1364~1367 (2004)
151. Morgenstern LB, "Guidelines for the management of spontaneous intracerebral hemorrhage : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2010, pp.41, 2108~2129
152. Liu L, "Blood pressure reduction for the secondary prevention of stroke : a Chinese trial and a systematic review of the literature", Hypertens Res, 32, pp.1032~1040 (2009)
153. Lakhan SE, "Blood pressure lowering treatment for preventing stroke recurrence : a systematic review and meta-analysis", Int Arch Med, 2, pp.30~ (2009)
154. Progress Collaborative Group, "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack", Lancet, 358, pp.1033~1041 (2001)
155. Chen GJ, "The effects of calcium channel blockers in the prevention of stroke in adults with hypertension : a meta-analysis of data from 273, 543 participants in 31 randomized controlled trials", PLoS One, 8, pp.e57854~ (2013)
156. Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387, pp.957~967 (2016)
157. Arima H, "Lower target blood pressures are safe and effective for the prevention of recurrent stroke : the PROGRESS trial", J Hypertens, 24, pp.1201~1208 (2006)
158. Group SPSS, "Blood-pressure targets in patients with recent lacunar stroke : the SPS3randomised trial", Lancet, 382, pp.507~515 (2013)
159. Rashid P, "Blood pressure reduction and secondary prevention of stroke and other vascular events : a systematic review", Stroke, 34, pp.2741~2748 (2003)
160. PATS Collaborating Group, "Poststroke antihypertensive treatment study. A preliminary result", Chin Med J, 108, pp.8~ (1995)
161. Dong JY, "Erectile dysfunction and risk of cardiovascular disease : meta-analysis of prospective cohort studies", J Am Coll Cardiol, 58, pp.1378~1385 (2011)
162. Scranton RE, "Effect of treating erectile dysfunction on management of systolic hypertension", Am J Cardiol, 100, pp.459~463 (2007)
163. Nunes KP, "New insights into hypertension-associated erectile dysfunction", Curr Opin Nephrol Hypertens, 21, pp.163~170 (2012)
164. Manolis A, "Sexual dysfunction : the ‘prima ballerina’ of hypertension-related quality-of-life complications", J Hypertens, 26, pp.2074~2084 (2008)
165. Pickering TG, "Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents : a randomized controlled trial", Am J Hypertens, 17, pp.1135~1142 (2004)
166. McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349, pp.2387~2398 (2003)
167. Mancia G, "2007 guidelines for the management of arterial hypertension : the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)", Eur Heart J, 28, pp.1462~1536 (2007)
168. Kuklina EV, "Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007: reasons for concern?", Stroke, 42, pp.2564~2570 (2011)
169. Regitz-Zagrosek V, "European society of, gynecology. Association for European Paediatric Cardiology. German Society for Gender Medicine. ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the Management of Cardiovascular Diseases during pregnancy of the European Society of Cardiology (ESC)", Eur Heart J, 32, pp.3147~3197 (2011)
170. Excellence NIfHaC, "Hypertension in pregnancy", The management of hypertensive disorders during pregnancy, ~ (2011)
171. Reckelhoff JF, "Novel mechanisms responsible for postmenopausal hypertension", Hypertension, 43, pp.918~923 (2004)
172. Staessen JA, "The epidemiology of the association between hypertension and menopause", J Hum Hypertens, 12, pp.587~592 (1998)
173. Chasan-Taber L, "Prospective study of oral contraceptives and hypertension among women in the United States", Circulation, 94, pp.483~489 (1996)
174. Turnbull F, "Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials", Eur Heart J, 29, pp.2669~2680 (2008)
175. Barbe F, "Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea", Am J Respir Crit Care Med, 181, pp.718~726 (2010)
176. Martinez-Garcia MA, "Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension : the HIPARCO randomized clinical trial", JAMA, 310, pp.2407~2415 (2013)
177. Lozano L, "Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension : a randomized, controlled trial", J Hypertens, 28, pp.2161~2168 (2010)
178. Pedrosa RP, "Effects of OSA treatment on BP in patients with resistant hypertension : a randomized trial", Chest, 144, pp.1487~1494 (2013)
179. Pedrosa RP, "Obstructive sleep apnea : the most common secondary cause of hypertension associated with resistant hypertension", Hypertension, 58, pp.811~817 (2011)
180. Peters R, "Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment(HYVET-COG) : a doubleblind, placebo controlled trial", Lancet Neurol, 7, pp.683~689 (2008)
181. Applegate WB, "Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program", Arch Intern Med, 154, pp.2154~2160 (1994)
182. Forette F, "Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe(Syst-Eur)trial", Lancet, 352, pp.1347~1351 (1998)
183. Forette F, "The prevention of dementia with antihypertensive treatment : new evidence from the systolic hypertension in Europe(Syst-Eur)study", Arch Intern Med, 162, pp.2046~2052 (2002)
184. Tzourio C, "Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease", Arch Intern Med, 163, pp.1069~1075 (2003)
185. Qiu C, "The age-dependent relation of blood pressure to cognitive function and dementia", Lancet Neurol, 4, pp.487~499 (2005)
186. Kuller LH, "Determinants of vascular dementia in the cardiovascular health cognition study", Neurology, 64, pp.1548~1552 (2005)
187. Liao D, "Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC study. Atherosclerosis risk in communities study", Stroke, 27, pp.2262~2270 (1996)
188. Longstreth WT Jr, "Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study", Stroke, 27, pp.1274~1282 (1996)
189. O'Rourke MF, "Relationship between aortic stiffening and microvascular disease in brain and kidney : cause and logic of therapy", Hypertension, 46, pp.200~204 (2005)
190. Hughes TM, "Hypertension and its role in cognitive function : current evidence and challenges for the future", Am J Hypertens, 29, pp.149~157 (2016)

관련 논문AI추천